Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors.

López-Fernández MF, Altisent Roca C, Álvarez-Román MT, Canaro Hirnyk MI, Mingot-Castellano ME, Jiménez-Yuste V, Cid Haro AR, Pérez-Garrido R, Sedano Balbas C.

Thromb Haemost. 2016 May 2;115(5):872-95. doi: 10.1160/TH15-07-0568. Epub 2016 Feb 4. Review.

PMID:
26842562
2.

Inhibitors in haemophilia A: current management and open issues.

Haya S, Moret A, Cid AR, Cortina V, Casaña P, Cabrera N, Aznar JA.

Haemophilia. 2007 Dec;13 Suppl 5:52-60. doi: 10.1111/j.1365-2516.2007.01574.x. Review.

PMID:
18078398
3.

Prophylaxis in haemophilia with inhibitors: update from international experience.

Carcao M, Lambert T.

Haemophilia. 2010 Mar;16 Suppl 2:16-23. doi: 10.1111/j.1365-2516.2009.02198.x.

PMID:
20132334
4.

Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.

Villarrubia R, Oyagüez I, Álvarez-Román MT, Mingot-Castellano ME, Parra R, Casado MA.

Haemophilia. 2015 May;21(3):320-9. doi: 10.1111/hae.12681. Epub 2015 Apr 9.

PMID:
25855214
5.

Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to FVIII.

Carpenter SL, Khair K, Gringeri A, Valentino LA.

Haemophilia. 2018 Jul;24(4):570-577. doi: 10.1111/hae.13534. Epub 2018 Jun 14. Review.

PMID:
29901839
6.

Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.

Abbonizio F, Giampaolo A, Coppola A; Italian Association of Haemophilia Centres, Arcieri R, Hassan HJ.

Haemophilia. 2014 Jul;20(4):e243-50. doi: 10.1111/hae.12456. Epub 2014 May 19.

PMID:
24834967
7.

A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.

Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ, Hay JW.

J Manag Care Spec Pharm. 2016 Feb;22(2):149-57. doi: 10.18553/jmcp.2016.22.2.149.

8.

Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors.

Mingot-Castellano ME, Álvarez-Román MT, López-Fernández MF, Altisent-Roca C, Canaro-Hirnyk MI, Jiménez-Yuste V, Cid-Haro AR, Pérez-Garrido R, Sedano-Balbas C.

Eur J Haematol. 2016 May;96(5):461-74. doi: 10.1111/ejh.12730. Epub 2016 Feb 4. Review.

PMID:
26714021
9.

Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.

Jiménez-Yuste V, Alvarez MT, Martín-Salces M, Quintana M, Rodriguez-Merchan C, Lopez-Cabarcos C, Velasco F, Hernández-Navarro F.

Haemophilia. 2009 Jan;15(1):203-9. doi: 10.1111/j.1365-2516.2008.01915.x.

PMID:
19149850
10.

Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors.

Ewing N, Escuriola-Ettingshausen C, Kreuz W.

Haemophilia. 2015 May;21(3):358-64. doi: 10.1111/hae.12602. Epub 2015 Jan 21.

PMID:
25603840
11.

Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor.

Croteau SE, Abajas YL, Wolberg AS, Nielsen BI, Marx GR, Baird CW, Neufeld EJ, Monahan PE.

Haemophilia. 2017 Mar;23(2):e93-e98. doi: 10.1111/hae.13157. Epub 2017 Jan 25.

12.

Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.

Kenet G, Oladapo A, Epstein JD, Thompson C, Novack A, Nugent DJ.

Haemophilia. 2017 Sep;23(5):e394-e402. doi: 10.1111/hae.13294. Epub 2017 Jun 22.

PMID:
28641362
13.

Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?

Brackmann HH, Effenberger W, Hess L, Schwaab R, Oldenburg J.

Eur J Haematol Suppl. 1998;63:18-23. Review.

PMID:
9882928
14.

Experiences in the prevention of arthropathy in haemophila patients with inhibitors.

Jimenez-Yuste V, Rodriguez-Merchan EC, Alvarez MT, Quintana M, Martin-Salces M, Hernandez-Navarro F.

Haemophilia. 2008 Nov;14 Suppl 6:28-35. doi: 10.1111/j.1365-2516.2008.01887.x. Review.

PMID:
19134031
15.

Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.

Mathieu S, Crampe C, Dargaud Y, Lavigne-Lissalde G, Escuriola-Ettingshausen C, Tardy B, Meley R, Thouvenin S, Stephan JL, Berger C.

Blood Coagul Fibrinolysis. 2015 Dec;26(8):940-5. doi: 10.1097/MBC.0000000000000300.

PMID:
26517064
16.

Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.

Livnat T, Martinowitz U, Azar-Avivi S, Zivelin A, Brutman-Barazani T, Lubetsky A, Kenet G.

Haemophilia. 2013 Sep;19(5):782-9. doi: 10.1111/hae.12181. Epub 2013 May 10.

PMID:
23659442
17.

Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.

Klintman J, Astermark J, Berntorp E.

Br J Haematol. 2010 Nov;151(4):381-6. doi: 10.1111/j.1365-2141.2010.08378.x. Epub 2010 Oct 1.

PMID:
20977448
18.

Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study.

Zanon E, Milan M, Gamba G, Ambaglio C, Saggiorato G, Spiezia L, Montani N, Prandoni P.

Thromb Res. 2015 Dec;136(6):1299-302. doi: 10.1016/j.thromres.2015.10.032. Epub 2015 Oct 22.

PMID:
26505666
19.
20.

A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors.

Putnam KG, Bohn RL, Ewenstein BM, Winkelmayer WC, Avorn J.

Haemophilia. 2005 May;11(3):261-9.

PMID:
15876272

Supplemental Content

Support Center